VKTX vs. MRNA

Last updated Jun 12, 2026

VKTX (Viking Therapeutics, Inc.) and MRNA (Moderna, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, VKTX returned 36.31%/yr vs -25.67%/yr for MRNA. At a 0.27 correlation, their price movements are largely independent.

Performance

VKTX vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Viking Therapeutics, Inc. (VKTX) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, VKTX achieves a -18.68% return, which is significantly lower than MRNA's 68.33% return.

VKTX

• 1D: 3.10%
• 1M: -8.65%
• YTD: -18.68%
• 6M: -23.11%
• 1Y: -1.17%
• 3Y*: 6.42%
• 5Y*: 36.31%
• 10Y*: 36.76%

MRNA

• 1D: 7.94%
• 1M: -6.81%
• YTD: 68.33%
• 6M: 67.53%
• 1Y: 78.88%
• 3Y*: -26.20%
• 5Y*: -25.67%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

VKTX vs. MRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
VKTX Viking Therapeutics, Inc.	-18.68%	-12.57%	116.23%	97.98%	104.35%	-18.29%	-29.80%	4.84%	-23.96%
MRNA Moderna, Inc.	68.33%	-29.08%	-58.19%	-44.63%	-29.28%	143.11%	434.10%	28.09%	-30.59%

Correlation

The correlation between VKTX and MRNA is 0.44, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.44
Correlation (3Y) Calculated over the trailing 3-year period	0.31
Correlation (5Y) Calculated over the trailing 5-year period	0.29
Correlation (All Time) Calculated using the full available price history since Dec 7, 2018	0.27

The correlation between VKTX and MRNA shifts across timeframes, from 0.27 (all time) to 0.44 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap VKTX : $3.31B MRNA : $19.61B
EPS VKTX : -$4.16 MRNA : -$8.16
PB Ratio VKTX : 6.59 MRNA : 2.65
Total Revenue (TTM) VKTX : $0.00 MRNA : $2.23B
Gross Profit (TTM) VKTX : -$208.00K MRNA : -$309.00M
EBITDA (TTM) VKTX : -$501.77M MRNA : -$3.02B

Return for Risk

VKTX vs. MRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VKTX

VKTX Risk / Return Rank: 44
VKTX Sharpe Ratio Rank: 43
VKTX Sortino Ratio Rank: 45
VKTX Omega Ratio Rank: 48
VKTX Calmar Ratio Rank: 42
VKTX Martin Ratio Rank: 42

MRNA

MRNA Risk / Return Rank: 78
MRNA Sharpe Ratio Rank: 80
MRNA Sortino Ratio Rank: 79
MRNA Omega Ratio Rank: 75
MRNA Calmar Ratio Rank: 79
MRNA Martin Ratio Rank: 75

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VKTX vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Viking Therapeutics, Inc. (VKTX) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	VKTX	MRNA	Difference
Sharpe ratio: Return per unit of total volatility	-0.02	1.22	-1.24
Sortino ratio: Return per unit of downside risk	0.52	2.07	-1.55
Omega ratio: Gain probability vs. loss probability	1.08	1.23	-0.15
Calmar ratio: Return relative to maximum drawdown	-0.03	2.23	-2.26
Martin ratio: Return relative to average drawdown	-0.05	4.39	-4.44

VKTX vs. MRNA - Sharpe Ratio Comparison

The current VKTX Sharpe Ratio is -0.02, which is lower than the MRNA Sharpe Ratio of 1.22. The chart below compares the historical Sharpe Ratios of VKTX and MRNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

VKTX vs. MRNA - Drawdown Comparison

The maximum VKTX drawdown since its inception was -90.41%, smaller than the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for VKTX and MRNA.

Drawdown Indicators

	VKTX	MRNA	Difference
Max Drawdown Largest peak-to-trough decline	-90.41%	-95.38%	+4.97%
Max Drawdown (1Y) Largest decline over 1 year	-45.14%	-35.51%	-9.63%
Max Drawdown (3Y) Largest decline over 3 years	-78.86%	-86.58%	+7.72%
Max Drawdown (5Y) Largest decline over 5 years	-78.86%	-95.38%	+16.52%
Max Drawdown (10Y) Largest decline over 10 years	-89.26%	—	—
Current Drawdown Current decline from peak	-69.72%	-89.75%	+20.03%
Average Drawdown Average peak-to-trough decline	-60.01%	-57.04%	-2.97%
Ulcer Index Depth and duration of drawdowns from previous peaks	22.80%	18.06%	+4.74%

Volatility

VKTX vs. MRNA - Volatility Comparison

The current volatility for Viking Therapeutics, Inc. (VKTX) is 15.32%, while Moderna, Inc. (MRNA) has a volatility of 18.37%. This indicates that VKTX experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VKTX	MRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.32%	18.37%	-3.05%
Volatility (6M) Calculated over the trailing 6-month period	40.84%	48.88%	-8.04%
Volatility (1Y) Calculated over the trailing 1-year period	74.00%	64.75%	+9.25%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	101.60%	66.52%	+35.08%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	97.02%	72.17%	+24.85%

Dividends

VKTX vs. MRNA - Dividend Comparison

Neither VKTX nor MRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both VKTX and MRNA in my portfolio?

VKTX and MRNA have a correlation of 0.44, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, VKTX or MRNA?

MRNA has higher volatility (18.37%) compared to VKTX (15.32%). In terms of maximum drawdown, VKTX dropped -90.41% vs MRNA's -95.38%.

Which has better risk-adjusted returns?

MRNA currently has the higher Sharpe Ratio (1.22 vs -0.02), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.